Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized active-controlled study of WX-081 versus bedaquiline in rifampicin-resistant pulmonary tuberculosis
CTR20221162Phase 3Active
- Sponsor
- Cisen Pharmaceutical Co., Ltd.
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sudapyridine in Rifampicin-resistant pulmonary tuberculosis (RR-PTB), pulmonary tuberculosis (TB), sponsored by Cisen Pharmaceutical Co., Ltd.. Started Sep 2022; status: active.
02
Drugs
sudapyridine
03
Conditions
Rifampicin-resistant pulmonary tuberculosis (RR-PTB)pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on CTR20221162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221162.